Terumo Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Terumo wird ein jährliches Gewinn- und Umsatzwachstum von 12.1% bzw. 5.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.1% betragen.

Wichtige Informationen

12.1%

Wachstumsrate der Gewinne

12.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	12.8%
Wachstumsrate der Einnahmen	5.8%
Zukünftige Eigenkapitalrendite	11.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 11

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 11

Recent updates

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 11

Returns At Terumo (TSE:4543) Appear To Be Weighed Down

Nov 08

Estimating The Fair Value Of Terumo Corporation (TSE:4543)

Sep 16

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Aug 11

Gewinn- und Umsatzwachstumsprognosen

TSE:4543 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	1,170,253	172,064	124,780	222,922	14
3/31/2026	1,090,644	152,151	109,870	206,874	15
3/31/2025	1,020,231	130,713	85,218	161,661	13
9/30/2024	986,674	119,486	114,170	193,649	N/A
6/30/2024	964,805	117,716	92,134	170,598	N/A
3/31/2024	921,863	106,374	67,556	146,330	N/A
12/31/2023	885,167	99,042	60,490	133,870	N/A
9/30/2023	860,767	99,096	35,316	110,769	N/A
6/30/2023	838,121	89,476	30,037	105,606	N/A
3/31/2023	820,209	89,325	45,363	117,536	N/A
12/31/2022	797,814	87,297	47,491	117,976	N/A
9/30/2022	761,982	79,146	65,356	135,078	N/A
6/30/2022	728,927	83,316	65,052	134,924	N/A
3/31/2022	703,303	88,813	67,362	141,467	N/A
12/31/2021	688,696	90,363	69,610	146,371	N/A
9/30/2021	675,183	95,414	69,307	146,611	N/A
6/30/2021	654,260	91,161	53,415	133,980	N/A
3/31/2021	613,842	77,268	38,573	121,485	N/A
12/31/2020	607,381	76,919	27,594	117,626	N/A
9/30/2020	604,915	71,342	20,121	109,392	N/A
6/30/2020	607,669	76,422	28,116	115,667	N/A
3/31/2020	628,897	85,211	33,995	117,479	N/A
12/31/2019	626,016	89,868	35,756	109,420	N/A
9/30/2019	621,762	90,727	34,047	104,160	N/A
6/30/2019	608,987	84,170	38,464	100,340	N/A
3/31/2019	599,481	79,470	39,207	93,571	N/A
12/31/2018	594,429	84,305	N/A	N/A	N/A
9/30/2018	588,162	92,782	61,609	106,706	N/A
6/30/2018	591,483	93,095	N/A	N/A	N/A
3/31/2018	587,775	91,295	N/A	114,562	N/A
12/31/2017	576,725	85,888	N/A	N/A	N/A
9/30/2017	553,664	66,769	N/A	87,995	N/A
6/30/2017	528,957	60,406	N/A	N/A	N/A
3/31/2017	514,164	54,225	N/A	80,862	N/A
12/31/2016	503,429	39,014	N/A	N/A	N/A
9/30/2016	510,969	44,087	N/A	85,463	N/A
6/30/2016	520,885	46,282	N/A	N/A	N/A
3/31/2016	525,026	50,676	N/A	80,303	N/A
12/31/2015	522,296	48,528	N/A	N/A	N/A
9/30/2015	515,364	43,603	N/A	80,102	N/A
6/30/2015	503,221	44,580	N/A	N/A	N/A
3/31/2015	489,506	38,470	N/A	73,110	N/A
12/31/2014	485,301	30,626	N/A	N/A	N/A
9/30/2014	474,640	36,517	N/A	86,298	N/A
6/30/2014	471,214	33,534	N/A	N/A	N/A
3/31/2014	467,360	34,096	N/A	96,260	N/A
12/31/2013	451,805	59,203	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4543Das prognostizierte Gewinnwachstum (12.1% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: 4543Die Erträge des Unternehmens (12.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (7.9% pro Jahr).

Hohe Wachstumserträge: 4543Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4543Die Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (4.1% pro Jahr).

Hohe Wachstumseinnahmen: 4543Die Einnahmen des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4543Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.1%).

Terumo Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

Price target increased by 10% to JP¥3,255

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Price target increased by 7.3% to JP¥5,548

Recent updates

Terumo Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Returns At Terumo (TSE:4543) Appear To Be Weighed Down

Second quarter 2025 earnings: EPS misses analyst expectations

Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024

Upcoming dividend of JP¥13.00 per share

Estimating The Fair Value Of Terumo Corporation (TSE:4543)

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.

Terumo Corporation Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 22%

Now 22% undervalued after recent price drop

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Final dividend of JP¥13.00 announced

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Terumo (TSE:4543) Has A Pretty Healthy Balance Sheet

Less than half of directors are independent

Return Trends At Terumo (TSE:4543) Aren't Appealing

Now 20% overvalued

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to JP¥3,255

Calculating The Fair Value Of Terumo Corporation (TSE:4543)

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Terumo (TSE:4543) Has Announced A Dividend Of ¥22.00

New minor risk - Dividend sustainability

Upcoming dividend of JP¥22.00 per share

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Is Terumo (TSE:4543) Using Too Much Debt?

Price target increased by 7.3% to JP¥5,548

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 26, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Upcoming dividend of JP¥22.00 per share at 1.1% yield

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥21.00 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥18.00 per share

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Less than half of directors are independent

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Full year 2022 earnings: EPS misses analyst expectations

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Less than half of directors are independent

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥16.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022